|
Sex
|
Age (years)
|
No. of participants
|
VCA-IgA [cases (%)]
|
χ2
|
P
|
|---|
|
–
|
1:5
|
1:10
|
1:20
|
≥1:40
|
|---|
|
Male
|
30–39
|
3063
|
2861 (93.4)
|
108 (3.5)
|
69 (2.3)
|
16 (0.5)
|
9 (0.3)
| | |
|
40–49
|
2196
|
2022 (92.1)
|
68 (3.1)
|
76 (3.5)
|
23 (1.0)
|
7 (0.3)
|
11.844
|
0.001
|
|
50–59
|
1740
|
1584 (91.0)
|
73 (4.2)
|
57 (3.3)
|
16 (0.9)
|
10 (0.6)
| | |
|
Female
|
30–39
|
5541
|
5225 (94.3)
|
139 (2.5)
|
129 (2.3)
|
27 (0.5)
|
21 (0.4)
| | |
|
40–49
|
3070
|
2855 (93.0)
|
93 (3.0)
|
83 (2.7)
|
24 (0.8)
|
15 (0.5)
|
15.475
|
0.000
|
|
50–59
|
2676
|
2463 (92.0)
|
96 (3.6)
|
71 (2.7)
|
30 (1.1)
|
16 (0.6)
| | |
-
VCA-IgA immunoglobulin A (IgA) antibodies against viral capsid antigen of Epstein–Barr virus (EBV)
